View all cases
- Case details
- Status—ActionPreliminary objectionCategoryPreliminary objection
- Parties
- Claimants
- BioMarin Pharmaceutical Inc.Operating co.
Representatives- Christian Paul-Jones Day
- Tobias Mandler-Jones Day
- Pascal Grandé-Jones Day
- Jason Raeburnsupporting-PAUL HASTINGS
- Alex Morgansupporting-PAUL HASTINGS
- Olga Bezzubova-Jones Day
- Ping Li-Jones Day
- Sven Rihm-Jones Day
Respondents- Ascendis Pharma A/SOperating co.
- Ascendis Pharma Growth Disorders A/SOperating co.
Representatives- Agathe Michel-De Cazotte-Carpmaels & Ransford
- Anna Leathley-Carpmaels & Ransford
- Daniel Wiese-Carpmaels & Ransford
- Division
- Munich LD
- Judges
- Technology
- ChemistryBiotechnology · Pharmaceuticals
- InstrumentsAnalysis of biological materials
- Language
- —
- First decided
- Apr 2, 2025
- EPO Opposition
- Ascendis Pharma Growth Disorders A/SAdmissible2022-09-01
- ASCENDIS PHARMA A/SIntervention2025-04-10
How this compares
How long the court takes to reach a first decision.
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| Munich LD | Locked |
| Judge Matthias Zigann | Locked |
At the UPC: BioMarin Pharmaceutical Inc. (3 cases)·Ascendis Pharma A/S (3 cases)
Start 14-day free trialAlready a user? Sign in
Related cases
All proceedings on this patentThis dispute contains 2 other proceedings
Decisions
- 2025-04-02Preliminary objectionPublic
Summary: The Munich Local Division rejected Ascendis Pharma's preliminary objection to jurisdiction in the infringement action brought by BioMarin Pharmaceutical concerning EP 3 175 863 (C-Type Natriuretic Peptide variants for achondroplasia treatment). The court found that the opt-out withdrawal was effective and that sufficient acts of infringement were alleged in Germany.
Show the legal issues (5)
- Preliminary objection to jurisdiction
- Opt-out withdrawal
- Acts of infringement in Germany
- Achondroplasia treatment
- TransCon CNP
Documents
- 18EFA19AFDEEB4870D662BC48DC08BCB_en.pdf2025-04-02EN